Concert Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Concert Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).

24 total trials none currently recruiting 24 completed early-phase tilt top decile by trial count

Concert Pharmaceuticals: 24 sponsored US clinical trials, none currently recruiting.

Concert Pharmaceuticals sponsors 24 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 24 completed. 2 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Health Volunteers, with 2 trials.

Top-decile sponsor footprint

Concert Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

24 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

24 total, page 1 of 1

COMPLETED Phase 1

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

NCT05478772
COMPLETED Phase 1

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

NCT05467709
COMPLETED Phase 1

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

NCT05467696
COMPLETED Phase 1

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

NCT05468749
COMPLETED Phase 1

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

NCT05467722
COMPLETED Phase 1

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369
COMPLETED Phase 3

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

NCT04797650
COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

NCT04843540
COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

NCT04743414
COMPLETED Phase 2

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
COMPLETED Phase 3

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

NCT04518995
COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
COMPLETED Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687
COMPLETED Phase 1

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
COMPLETED Phase 2

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548
COMPLETED Phase 1

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

NCT03880253
COMPLETED Phase 1

Food Effect Study of CTP-543 in Healthy Volunteers

NCT03880136
COMPLETED Phase 2

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
COMPLETED Phase 1

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

NCT03830463
COMPLETED Phase 2

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

NCT03137381
COMPLETED Phase 1

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

NCT02960945
COMPLETED Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109
COMPLETED Phase 1

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199
COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 6
Phase 3 2

Therapeutic Areas

Health Volunteers 2
Healthy Volunteers 1
Healthy 1

How the Concert Pharmaceuticals early-phase archive is shaped

24 indexed studies, none listed as recruiting (0% open); 24 completed (100%).

Phase mix: 2 late (III/IV) vs 22 early (I/II) (early-phase heavy).

Top condition: Health Volunteers (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Concert Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 24 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015202530 0%10%20%30% Total trials Recruiting share Concert PharmaceuticalsAcrotech BiopharmaAgenusAkebia TherapeuticsBlueprint Medicines Corporation10xBio22nd Century Group23andMe3-C Institute for Social Development
Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 24 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Concert Pharmaceuticals page

24 registered trials is a research-attention snapshot, not an endorsement of Concert Pharmaceuticals or any single study.

  • None of Concert Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Health Volunteers is the condition Concert Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Health Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Concert Pharmaceuticals pipeline card: 24 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.